A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and
antiangiogenic activities. This study is designed to evaluate the safety and tolerability of
Famitinib in patients with solid tumor
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Collaborators:
Chinese Academy of Medical Sciences Chinese Academy of Sciences